Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.

Autor:	Norton N; 1Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 USA., Youssef B; 1Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 USA., Hillman DW; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905 USA., Nassar A; 3Department of Pathology, Mayo Clinic, Jacksonville, FL 32224 USA., Geiger XJ; 3Department of Pathology, Mayo Clinic, Jacksonville, FL 32224 USA., Necela BM; 1Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224 USA., Liu H; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905 USA., Ruddy KJ; 4Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA., Polley MC; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905 USA., Ingle JN; 4Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA., Couch FJ; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905 USA.; 5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905 USA., Perez EA; 6Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224 USA., Liu MC; 4Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA.; 5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905 USA., Carter JM; 5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905 USA., Leon-Ferre RA; 4Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA., Boughey JC; 7Department of Surgery, Mayo Clinic, Rochester, MN 55905 USA., Somers EB; 8Eisai, Inc, Exton, PA 19341 USA., Kalari KR; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905 USA., Visscher DW; 5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905 USA., Goetz MP; 4Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA.; 9Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA., Knutson KL; 10Department of Immunology, Mayo Clinic, Jacksonville, FL 32246 USA.
Jazyk:	angličtina
Zdroj:	NPJ breast cancer [NPJ Breast Cancer] 2020 Feb 04; Vol. 6, pp. 4. Date of Electronic Publication: 2020 Feb 04 (Print Publication: 2020).
DOI:	10.1038/s41523-020-0147-1
Abstrakt:	Triple negative breast cancer (TNBC) comprises 15-20% of all invasive breast cancer and is associated with a poor prognosis. As therapy options are limited for this subtype, there is a significant need to identify new targeted approaches for TNBC patient management. The expression of the folate receptor alpha (FRα) is significantly increased in patients with TNBC and is therefore a potential biomarker and therapeutic target. We optimized and validated a FRα immunohistochemistry method, specific to TNBC, to measure FRα expression in a centrally confirmed cohort of 384 patients with TNBC in order to determine if expression of the protein is associated with invasive disease-free survival (IDFS) and overall survival (OS). The FRα IHC demonstrated exceptional performance characteristics with low intra- and interassay variability as well as minimal lot-to-lot variation. FRα expression, which varied widely from sample to sample, was detected in 274 (71%) of the TNBC lesions. In a multivariable model adjusted for baseline characteristics, FRα expression was associated with improved IDFS (HR = 0.63, p  = 0.01) but not with OS. The results demonstrate the potential of targeting the FRα in the majority of TNBC patients and suggest that variable expression may point to a need to stratify on FRα expression in clinical studies. Competing Interests: Competing interestsThe authors declare no competing interests. (© The Author(s) 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu